Inhibition of circulating BMP1-3 in an animal CKD model with specific BMP1-3 polyclonal antibodies, as opposed to rats treated with the BMP1-3 protein, increased the overall survival rate by 60% and significantly reduced the level of kidney fibrosis and glomerular sclerosis, indicating a high benefit of the therapeutic intervention [12]. This evidence concerns the gene GDF6 and chronic kidney disease.